Health Care · Pharmaceutical Preparations

NRIX Nurix Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1549595110 filings
Russell 2000

NRIX at a glance

Nurix Therapeutics, Inc. (NRIX, SEC CIK 1549595) filed its latest 10-K annual report on January 28, 2026, a 10-Q quarterly report on October 13, 2026, an 8-K current report on November 3, 2026 and Form 4 insider filings as recently as November 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended November 30, 2025 (FY2025), Nurix Therapeutics, Inc. (NRIX) reported revenue of $84.0 million (up 54.0% from FY2024) and a net loss of $264.5 million. Diluted EPS was -$3.05.
  • As of September 30, 2026, 29 institutional investment managers tracked by SignalX reported holding Nurix Therapeutics, Inc. (NRIX) shares worth $913.8 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by van Houte Hans on November 4, 2026 of 3,300 shares at $15.38 per share.
  • In the last 90 days, NRIX insiders reported 0 open-market purchases ($0) and 15 open-market sales ($1.7M) on Form 4, a net sale of $1.7M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$84.0M
+54.0% vs prior year
Insiders · 90 days
0 buys · 15 sells
Net −$1.7M
13F holders
29 funds
$913.8M · +1 vs prior quarter
Latest 8-K
Nov 3, 2026
Item 8.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Nov 30, 2025

Full analysis →

Business Overview

  • Clinical stage biopharma focused on targeted protein degradation using AI-integrated DEL-AI platform for oncology, inflammation, and immunology treatments
  • Advanced lead BTK degrader bexobrutideg in Phase 2 pivotal trial with FDA Fast Track and EMA PRIME designations for relapsed/refractory CLL and WM
  • Resumed Phase 1 study of dual BTK/Ikaros/Aiolos degrader zelebrudomide after FDA partial clinical hold lifted in 2024
  • $482M non-dilutive funding through collaborations with Gilead, Sanofi, Pfizer; potential $6.1B future milestones and royalties
  • Introduced oral CBL-B inhibitor NX-1607 in Phase 1 trials for solid tumors and gained UK Innovation Passport in 2022 for accelerated market access

Risk Factors

  • Regulatory risk: FDA partial clinical hold on zelebrudomide enrollment in 2023 due to manufacturing change, lifted in August 2024
  • Macroeconomic risk: Uncertainty from inflation, interest rates, tariffs, debt ceiling risks, and global conflict impacts clinical trials, supply chain, personnel
  • Operational risk: Dependency on third-party manufacturing for chirally controlled zelebrudomide form critical to ongoing Phase 1b dose escalation
  • Market disruption risk: Competitive threat from established BTK inhibitors and non-covalent BTK inhibitors used in relapsed/refractory CLL patients
  • Financial risk: Net losses of $264.5 million in FY 2025 with $592.9 million cash runway for only 12 months, needing substantial additional capital beyond that

Management Discussion & Analysis

  • Forward-looking statements mention risks and uncertainties without specific guidance or outlook

AI summary of the NRIX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Aug 31, 2026

Management Discussion & Analysis

  • Revenue $673.1M, up $665.2M YoY, driven by $653.2M Roche license revenue
  • Net income $549.8M vs $86.4M loss YoY, operating margin 83.1% vs negative 1,157.6%
  • Roche collaboration best contributor: $653.2M license revenue, versus Pfizer collaboration revenue $9.7M
  • Operating cash flow $447.1M vs $181.6M use YoY, cash and securities $1.1B
  • Near-term funding sufficient for at least 12 months, with substantial additional capital required long term

Risk Factors

  • Newly added commercialization risk: Roche collaboration triggered transition to commercial operations, requiring new sales, compliance and market-access capabilities
  • Most materially updated clinical risk: Phase 3 DAYBreak CLL-306 enrolled its first patient in August 2026, expanding exposure to late-stage safety findings
  • Regulatory risk: Loper Bright increased litigation and judicial scrutiny of FDA, CMS and HHS interpretations, potentially affecting future pricing and reimbursement
  • Competitive risk: Multiple BTK degrader programs now in clinical development, increasing pressure on bexobrutideg’s market opportunity
  • Liquidity risk: $1.1 billion in cash, equivalents and marketable securities supports operations through at least the next 12 months, but additional funding remains necessary long term

AI summary of the NRIX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 3, 2026Full analysis →

Item 8.01: Other Events

  • Sanofi discontinued the Phase 1 trial and terminated SAR448272, an oral STAT6 degrader
  • Nurix loses eligibility for future development, regulatory and commercial milestones and royalties tied to SAR448272
Filed Oct 13, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release announces Nurix Therapeutics’ financial results for the quarter ended August 31, 2026
  • Exhibit 99.1 contains the underlying financial results and management commentary for investor review

Item EX-99.1: Item EX-99.1

  • Revenue $673.1M, including $653.2M Roche license revenue and $10.0M Sanofi milestone
  • Net income $549.8M, or $4.73 diluted EPS, versus $86.4M net loss in the prior-year quarter
Filed Jul 9, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Nurix announced fiscal-quarter results for the period ended May 31, 2026
  • Full financial details and management commentary are contained in Exhibit 99.1, the accompanying press release

Item EX-99.1: Item EX-99.1

  • Roche collaboration: $700M upfront and up to $2.3B total payments for bexobrutideg, subject to closing conditions
  • Development costs shared 40% Nurix and 60% Roche, with equal U.S. profit/loss sharing and tiered ex-U.S. royalties

AI summaries of NRIX 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for NRIX

Don't miss the next NRIX filing

  • Alerts as it files. A push when NRIX files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut NRIX, by share count.
  • Ask anything. An AI agent that reads every NRIX filing and answers with sources.

NRIX alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
van Houte HansSellNov 4, 2026$15.38
van Houte HansSellNov 4, 2026$16.20
Ring ChristineSellNov 3, 2026$25.83
Ring ChristineSellNov 2, 2026$25.74
Hansen GwennMNov 2, 2026$1.86
Ring ChristineSellNov 2, 2026$26.76
Hansen GwennMNov 2, 2026-
Hansen GwennSellNov 2, 2026$26.80

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$77.0M$54.5M$84.0M
Operating Income--$213.0M-$285.7M
Net Income-$143.9M-$193.6M-$264.5M
Op. Margin--390.5%-340.2%
Net Margin-187.0%-354.9%-314.9%
Balance Sheet
Total Assets-$669.3M$688.1M
Equity-$527.0M$538.7M
ROE--36.7%-49.1%
Per Share
EPS$-2.65$-2.88$-3.05
Cash Flow
Operating CF--$172.6M-$249.5M
CapEx$8.4M$9.3M$14.0M

Source: XBRL data in Nurix Therapeutics, Inc. (NRIX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate NRIX share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
NRIX shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202629$913.8M
Q2 202628$1.08B
Q1 202628$662.3M
Q4 202521$718.2M
Q3 202524$306.3M
Q2 202525$414.5M
Q1 202524$308.9M
Q4 202420$426.5M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 199 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

NRIX filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 4, 2026--
4Nov 4, 2026--
8-KNov 3, 2026Analysis-
4Nov 2, 2026--
4Nov 2, 2026--
4Nov 2, 2026--
4Oct 15, 2026--
4Oct 14, 2026--
8-KOct 13, 2026Analysis-
10-QOct 13, 2026Analysis
4Oct 2, 2026--
SC 13GSep 23, 2026-
4Sep 2, 2026--
4Sep 1, 2026--
SC 13GAug 14, 2026-
SC 13GAug 14, 2026-
4Aug 5, 2026--
4Aug 5, 2026--
4Aug 4, 2026--
4Aug 3, 2026--
SC 13GJul 31, 2026-
4Jul 30, 2026--
4Jul 30, 2026--
4Jul 30, 2026--
8-KJul 9, 2026Analysis-

Related Health Care companies

All Health Care →

NRIX SEC filings: frequently asked questions

Are NRIX insiders buying or selling?

In the last 90 days, Nurix Therapeutics, Inc. (NRIX) officers, directors and 10% owners reported no open-market purchases and 15 open-market sales worth $1.7 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold NRIX stock?

As of September 30, 2026, the largest Nurix Therapeutics, Inc. (NRIX) holders among the 13F filers tracked by SignalX were BlackRock ($208.7 million), Morgan Stanley ($124.4 million), T. Rowe Price Group ($108.4 million), Vanguard Capital Management LLC ($106.8 million), State Street Corp ($105.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was NRIX's revenue in fiscal year 2025?

For the fiscal year ended November 30, 2025 (FY2025), Nurix Therapeutics, Inc. (NRIX) reported revenue of $84.0 million (up 54.0% from FY2024) and a net loss of $264.5 million. Diluted EPS was -$3.05. The figures come from the XBRL data in the 10-K.

What are the main risks in NRIX's latest 10-K?

In the 10-K filed January 28, 2026, Nurix Therapeutics, Inc. (NRIX) flagged: Regulatory risk: FDA partial clinical hold on zelebrudomide enrollment in 2023 due to manufacturing change, lifted in August 2024. Macroeconomic risk: Uncertainty from inflation, interest rates, tariffs, debt ceiling risks, and global conflict impacts clinical trials, supply chain, personnel. (AI summary of the Risk Factors section.)

What did NRIX report in its latest 8-K?

Nurix Therapeutics, Inc. (NRIX) filed an 8-K on November 3, 2026 reporting Item 8.01 (Other Events). Sanofi discontinued the Phase 1 trial and terminated SAR448272, an oral STAT6 degrader.

What are the latest NRIX SEC filings?

Nurix Therapeutics, Inc. (NRIX) filed its latest 10-K annual report on January 28, 2026, a 10-Q quarterly report on October 13, 2026, an 8-K current report on November 3, 2026 and a Form 4 insider filing on November 4, 2026.

What is NRIX's SEC CIK number?

Nurix Therapeutics, Inc. (NRIX)'s SEC Central Index Key (CIK) is 1549595. EDGAR lists every NRIX filing under that number.

Ask anything about NRIX

The research agent reads NRIX's filings, financials, insider trades and 13F holders, then answers with sources.